Posted by Michael Wonder on 23 Feb 2021
Amgen submits supplemental new drug application for Otezla (apremilast) for adults with mild to moderate plaque psoriasis
22 February 2021 - Filing based on data from Phase 3 ADVANCE trial.
Amgen today announced the submission of a supplemental new drug application to the U.S. FDA for Otezla (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy.
